SCI和EI收录∣中国化工学会会刊

中国化学工程学报 ›› 2021, Vol. 29 ›› Issue (2): 301-307.DOI: 10.1016/j.cjche.2020.11.009

• Biomedical Engineering • 上一篇    下一篇

Monoclonal antibody-based cancer therapies

Yingnan Si1, Arin L. Melkonian2, Keegan C. Curry1, Yuanxin Xu1, Maranda Tidwell1, Mingming Liu3, Ahmed F. Zaky4, Xiaoguang (Margaret) Liu1   

  1. 1 Department of Biomedical Engineering, University of Alabama at Birmingham(UAB), 1825 University Blvd, Birmingham, AL 35294, USA;
    2 Department of Medicine, UAB, 1720;
    2 nd Ave S., Birmingham, AL 35294, USA;
    3 Chinese Medicine Hospital, 98 Shengcheng Street, Shouguang 262700, China;
    4 Department of Anesthesiology and Perioperative Medicine, UAB, 625 19th Street South, Birmingham, AL 35294, USA
  • 收稿日期:2020-10-13 修回日期:2020-11-15 出版日期:2021-02-28 发布日期:2021-05-15
  • 通讯作者: Xiaoguang (Margaret) Liu
  • 基金资助:
    This work was supported by National Institutes of Health R21CA226491-01A1 (X.M.L.), 1R01CA238273-01A1 (X.M.L.) and 1R01CA242917-01A1 (X.M.L.).

Monoclonal antibody-based cancer therapies

Yingnan Si1, Arin L. Melkonian2, Keegan C. Curry1, Yuanxin Xu1, Maranda Tidwell1, Mingming Liu3, Ahmed F. Zaky4, Xiaoguang (Margaret) Liu1   

  1. 1 Department of Biomedical Engineering, University of Alabama at Birmingham(UAB), 1825 University Blvd, Birmingham, AL 35294, USA;
    2 Department of Medicine, UAB, 1720;
    2 nd Ave S., Birmingham, AL 35294, USA;
    3 Chinese Medicine Hospital, 98 Shengcheng Street, Shouguang 262700, China;
    4 Department of Anesthesiology and Perioperative Medicine, UAB, 625 19th Street South, Birmingham, AL 35294, USA
  • Received:2020-10-13 Revised:2020-11-15 Online:2021-02-28 Published:2021-05-15
  • Contact: Xiaoguang (Margaret) Liu
  • Supported by:
    This work was supported by National Institutes of Health R21CA226491-01A1 (X.M.L.), 1R01CA238273-01A1 (X.M.L.) and 1R01CA242917-01A1 (X.M.L.).

摘要: Targeted therapy has been widely demonstrated as an effective strategy to treat cancers, the leading cause of death in the world. This minireview summarizes the technical platforms and methodologies utilized to develop and engineer therapeutic monoclonal antibodies and antibody-drug conjugates. First, the USA FDA approved monoclonal antibody (mAb)-based targeted therapies are reviewed. Then the representative innovative chimeric, humanized and fully human anti-cancer antibodies and antibody-drug conjugates are described. Finally, the past and predictive market trend of therapeutic antibodies is discussed.

关键词: Monoclonal antibody, Antibody-drug conjugate, Anti-cancer therapy, Market

Abstract: Targeted therapy has been widely demonstrated as an effective strategy to treat cancers, the leading cause of death in the world. This minireview summarizes the technical platforms and methodologies utilized to develop and engineer therapeutic monoclonal antibodies and antibody-drug conjugates. First, the USA FDA approved monoclonal antibody (mAb)-based targeted therapies are reviewed. Then the representative innovative chimeric, humanized and fully human anti-cancer antibodies and antibody-drug conjugates are described. Finally, the past and predictive market trend of therapeutic antibodies is discussed.

Key words: Monoclonal antibody, Antibody-drug conjugate, Anti-cancer therapy, Market